IAI FigSearch
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rajagopalan, G.
Right arrow Articles by David, C. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rajagopalan, G.
Right arrow Articles by David, C. S.

 Previous Article  |  Next Article 

Infection and Immunity, October 2006, p. 6016-6019, Vol. 74, No. 10
0019-9567/06/$08.00+0     doi:10.1128/IAI.00671-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Acute Systemic Immune Activation following Conjunctival Exposure to Staphylococcal Enterotoxin B

Govindarajan Rajagopalan,1 Michele K. Smart,1 Robin Patel,2 and Chella S. David1*

Department of Immunology,1 Divisions of Infectious Diseases and Clinical Microbiology, Mayo Clinic College of Medicine, Rochester, Minnesota 559052

Received 26 April 2006/ Returned for modification 26 June 2006/ Accepted 3 July 2006


   ABSTRACT
Top
 Abstract
Text
 References
 
Conjunctival exposure to the Staphylococcus aureus superantigen staphylococcal enterotoxin B (SEB) may occur accidentally, as a result of bioterrorism, or during colonization or infection of the external eye. Using human leukocyte antigen class II transgenic mice, we show for the first time that conjunctival exposure to SEB can cause robust systemic immune activation.


   TEXT
Top
 Abstract
 Text
References
 
Staphylococcal enterotoxin B (SEB) is a superantigenic exotoxin produced by Staphylococcus aureus that is capable of inducing strong polyclonal activation of CD4+ and CD8+ T lymphocytes even at extremely low concentrations (23). The potent immunostimulatory property of SEB has led to its development as a biological weapon (4, 19), delivered either through contaminated food or water or in an aerosolized form. While ingested SEB causes acute food poisoning (2), airway exposure to SEB aerosol can cause robust systemic immune activation and a clinical condition resembling toxic shock (3, 20, 26, 29).

In the event of exposure to aerosolized SEB, the eyes, in addition to the airways, would also be readily exposed to SEB. In such a case, the conjunctival mucous membranes may serve as a portal of absorption of SEB. However, it is not known whether conjunctival exposure to SEB can have systemic effects. Isolated cases of accidental conjunctival SEB exposure do suggest systemic effects (30). This has potential clinical relevance in addition to its biodefense significance for the following reasons. Conjunctival exposure to SEB can occur during extraocular staphylococcal infections such as keratitis, conjunctivitis, or blepharitis, albeit in smaller amounts (10, 11, 14, 15, 18, 31, 32). Patients with atopic dermatitis particularly tend to have high levels of S. aureus in the conjunctival sacs and eyelid margins; these isolates are capable of elaborating superantigen exotoxins (12, 16, 21, 22, 36). The hemolytic alpha-, beta-, delta-, and gamma-toxins of S. aureus are produced during such extraocular infections and play a role in the etiopathogenesis of staphylococcal eye diseases (6, 7, 9, 13). Staphylococcal superantigen exotoxins are also produced during such infections (1, 33-35, 38), but their pathogenic role is unknown. Given these observations that conjunctival exposure to SEB can occur accidentally, as a result of bioterrorism, or during colonization or infection of the external eye, it is imperative to understand its systemic effects. Therefore, in the present study, we evaluated the systemic immune effects of conjunctival exposure to SEB. It should be noted that conventional mice mount a weak immune response to SEB due poor binding of SEB to endogenous murine major histocompatibility complex class II molecules (5, 8, 28, 29, 37). Nonetheless, transgenic mice expressing human leukocyte antigen-DR3 (HLA-DR3) or -DQ8 or the interleukin-10 (IL-10)-deficient HLA-DQ8 transgenic mice are extremely sensitive to immune activation by SEB (24-27) and hence were used in our study.

For conjunctival challenge, 5 µl of phosphate-buffered saline (PBS) alone or SEB (5 µg/µl, highly purified, endotoxin-reduced, <1 endotoxin unit/mg; Toxin Laboratories, Sarasota, FL) was instilled onto each eye of anesthetized mice, and the animals were sacrificed at specific time points. Conjunctival application of SEB caused a time-dependent alteration in the expression patterns of selected activation markers on CD4+ and CD8+ T cells bearing SEB-reactive TCR Vß8 in the draining cervical lymph nodes (Fig. 1). Although the expression of CD62L decreased by 24 h in SEB-treated mice, the level returned to that seen in PBS-treated mice by 72 h. Consistent with the activated phenotype, the expression of CD69 increased by 24 h, peaked by 48 h, and returned to low levels by 72 h. CD44, another activation marker, showed a similar profile (data not shown). The taller histogram peaks at 72 h in SEB-treated mice were due to the expansion of TCR Vß8-bearing T cells at this time point, resulting in higher cell counts (see below).


Figure 1
View larger version (33K):
[in this window]
[in a new window]
  		FIG. 1. Systemic T-cell activation after conjunctival exposure to SEB. Age-matched HLA-DQ8.IL-10–/– mice were anesthetized, and 5 µl (25 µg) of SEB was applied onto each eye. The expression of activation markers CD62L (A) and CD69 (B) on SEB-reactive TCR Vß8+ CD4+ and CD8+ T cells in the cervical lymph nodes at the indicated time points was determined by flow cytometry. Representative histograms from one of four similar experiments are shown.

 
Conjunctival application of SEB also resulted in an expansion of CD4+ and CD8+ T cells bearing the SEB-reactive TCR Vß8 but not of cells bearing the SEB-nonreactive TCR Vß6, in the draining cervical lymph nodes as well as in the spleen (Fig. 2), indicating a systemic response to SEB. It had been shown earlier that after systemic administration of superantigen (by intraperitoneal or intravenous routes), while peripheral T cells undergo expansion, CD4 CD8 double-positive thymocytes undergo massive deletion (17). As depicted in Fig. 3, there was a time-dependent reduction in the percentage of CD4 CD8 double-positive thymocytes (upper right quadrants) consistent with apoptosis of immature double-positive thymocytes, with a proportional increase in the percentages of CD4 and CD8 single-positive thymocytes (lower right and upper left quadrants, respectively). The absolute number of thymocytes was reduced by 15-fold by 72 h compared to PBS-treated mice.


Figure 2
View larger version (20K):
[in this window]
[in a new window]
  		FIG. 2. Peripheral T-cell expansion after conjunctival exposure to SEB. Age-matched HLA-DQ8.IL-10–/– mice were anesthetized, and 5 µl (25 µg) of SEB was applied onto each eye. Mice were sacrificed at the indicated time points, and the distribution of CD4+ and CD8+ T cells expressing TCR Vß6 (SEB-nonreactive) or Vß8 (SEB-reactive) in the cervical lymph nodes (A) and spleens (B) was analyzed by flow cytometry. Bars represent mean + the standard error from four to five mice/group.

 

Figure 3
View larger version (22K):
[in this window]
[in a new window]
  		FIG. 3. Thymocyte apoptosis after conjunctival exposure to SEB. Age-matched HLA-DQ8.IL-10–/– mice were anesthetized, and 5 µl (25 µg) of SEB was applied onto each eye. Mice were sacrificed at the indicated time points, and the distributions of thymocyte subsets were analyzed by flow cytometry. Representative dot plots from one of four similar experiments are shown.

 
Systemic immune activation after conjunctival exposure to SEB was also evident in HLA-DR3 transgenic mice as assessed by similar parameters (data not shown). In addition, HLA-DR3 transgenic mice were challenged conjunctivally with SEB and given bromodeoxyuridine (BrdU; Sigma, St. Louis, MO) daily in their drinking water at a concentration of 0.8 mg/ml. BrdU incorporated into newly synthesized DNA was detected by using a BrdU flow kit (Becton Dickinson, San Jose, CA). As depicted in Fig. 4, ocular instillation of SEB led to the proliferation of CD4+ and CD8+ T cells in the draining lymph nodes (Fig. 4), as well as in the spleen (data not shown), resulting in BrdU incorporation only in T cells bearing TCR Vß8 but not in T cells bearing TCR Vß6, further supporting a systemic effect of SEB delivered through the conjunctival mucosa. On the other hand, BrdU incorporation was indistinguishable between T cells bearing Vß6 and Vß8 in mice instilled with PBS. Thus, we have shown for the first time that conjunctival exposure to SEB can cause systemic immune activation.


Figure 4
View larger version (31K):
[in this window]
[in a new window]
  		FIG. 4. Peripheral T-cell expansion after conjunctival exposure to SEB. Age-matched HLA-DR3 transgenic mice were anesthetized, and 5 µl (25 µg) of SEB was applied onto each eye. Mice were treated with BrdU in drinking water daily and sacrificed at 72 h. BrdU incorporated in CD4+ and CD8+ T cells expressing TCR Vß6 (SEB-nonreactive) or Vß8 (SEB-reactive) in cervical lymph nodes in gated population (indicated by the circles) was analyzed by flow cytometry. Representative plots are shown. In histograms, shaded and clear areas represent BrdU incorporated in Vß6- and Vß8-gated cells, respectively.

 
The amount of SEB ultimately absorbed after conjunctival application in mice would be much lower than what was applied because of grooming activity. In spite of this fact, we were still able to show systemic immune activation. High levels of human exposure to SEB can occur during accidental laboratory exposure or during intentional bioterrorism. Nonetheless, it should also be noted that humans are far more sensitive to SEB than are HLA class II transgenic mice. For example, the estimated 50% lethal dose of aerosolized SEB is 0.02 µg/kg in humans (30), whereas that for HLA-DQ8 transgenic mice is 70 µg/kg (29). Thus, conjunctival exposure to smaller amounts of SEB as would occur during infections could probably have systemic effects in humans. Acute or chronic conjunctival exposure to SEB or even other superantigens after a staphylococcal eye colonization or infection or after exposure to aerosols likely has other implications, including the activation of autoreactive T cells and other immunological consequences similar to what we have we shown recently after exposure through the nasal route (24, 26).


   ACKNOWLEDGMENTS
 
We thank Julie Hanson and her coworkers for excellent mouse husbandry.

This study was supported by NIH grant AI14764. G.R. is the recipient of a Juvenile Diabetes Research Foundation fellowship.


   FOOTNOTES
 
* Corresponding author. Mailing address: Department of Immunology, Mayo Clinic College of Medicine, 200 First St., SW, Rochester, MN 55905. Phone: (507) 284-8180. Fax: (507) 266-0981. E-mail: davic4{at}mayo.edu. Back

Editor: J. T. Barbieri


   REFERENCES
Top
 Abstract
 Text
 References
 
1. Balaban, N., L. V. Collins, J. S. Cullor, E. B. Hume, E. Medina-Acosta, O. Vieira da Motta, R. Orsquo-Callaghan, P. V. Rossitto, M. E. Shirtliff, and L. Serafim da Silveira. 2000. Prevention of diseases caused by Staphylococcus aureus using the peptide Rip. Peptides 21:1301-1311.[CrossRef][Medline]
2. Balaban, N., and A. Rasooly. 2000. Staphylococcal enterotoxins. Int. J. Food Microbiol. 61:1-10.[CrossRef][Medline]
3. Boles, J. W., M. L. Pitt, R. D. LeClaire, P. H. Gibbs, R. G. Ulrich, and S. Bavari. 2003. Correlation of body temperature with protection against staphylococcal enterotoxin B exposure and use in determining vaccine dose-schedule. Vaccine 21:2791-2796.[CrossRef][Medline]
4. Burnett, J. C., E. A. Henchal, A. L. Schmaljohn, and S. Bavari. 2005. The evolving field of biodefense: therapeutic developments and diagnostics. Nat. Rev. Drug Discov. 4:281-297.[CrossRef][Medline]
5. Cole, B., A. Sawitzke, E. Ahmed, C. Atkin, and C. David. 1997. Allelic polymorphisms at the H-2A and HLA-DQ loci influence the response of murine lymphocytes to the Mycoplasma arthritidis superantigen Mam. Infect. Immun. 65:4190-4198.[Abstract]
6. Dajcs, J. J., M. S. Austin, G. D. Sloop, J. M. Moreau, E. B. H. Hume, H. W. Thompson, F. M. McAleese, T. J. Foster, and R. J. O'Callaghan. 2002. Corneal pathogenesis of Staphylococcus aureus strain Newman. Investig. Ophthalmol. Vis. Sci. 43:1109-1115.[Abstract/Free Full Text]
7. Dajcs, J. J., B. A. Thibodeaux, D. O. Girgis, and R. J. O'Callaghan. 2002. Corneal virulence of Staphylococcus aureus in an experimental model of keratitis. DNA Cell Biol. 21:375-382.[CrossRef][Medline]
8. DaSilva, L., B. C. Welcher, R. G. Ulrich, M. J. Aman, C. S. David, and S. Bavari. 2002. Humanlike immune response of human leukocyte antigen-DR3 transgenic mice to staphylococcal enterotoxins: a novel model for superantigen vaccines. J. Infect. Dis. 185:1754-1760.[CrossRef][Medline]
9. Dinges, M. M., P. M. Orwin, and P. M. Schlievert. 2000. Exotoxins of Staphylococcus aureus. Clin. Microbiol. Rev. 13:16-34.[Abstract/Free Full Text]
10. Donnenfeld, E. D., T. P. O'Brien, R. Solomon, H. D. Perry, M. G. Speaker, and J. Wittpenn. 2003. Infectious keratitis after photorefractive keratectomy. Ophthalmology 110:743-747.[CrossRef][Medline]
11. Durkin, S. R., D. Selva, S. C. Huilgol, S. Guy, and I. Leibovitch. 2006. Recurrent staphylococcal conjunctivitis associated with facial impetigo contagiosa. Am. J. Ophthalmol. 141:189-190.[CrossRef][Medline]
12. Fukuda, M., H. Ohashi, C. Matsumoto, S. Mishima, and Y. Shimomura. 2002. Methicillin-resistant Staphylococcus aureus and methicillin-resistant coagulase-negative staphylococcus ocular surface infection efficacy of chloramphenicol eye drops. Cornea 21:S86-S89.[Medline]
13. Girgis, D. O., G. D. Sloop, J. M. Reed, and R. J. O'Callaghan. 2005. Effects of toxin production in a murine model of Staphylococcus aureus keratitis. Investig. Ophthalmol. Vis. Sci. 46:2064-2070.[Abstract/Free Full Text]
14. Girgis, D. O., G. D. Sloop, J. M. Reed, and R. J. O'Callaghan. 2003. A new topical model of Staphylococcus corneal infection in the mouse. Investig. Ophthalmol. Vis. Sci. 44:1591-1597.[Abstract/Free Full Text]
15. Haas, J., E. Larson, B. Ross, B. See, and L. Saiman. 2005. Epidemiology and diagnosis of hospital-acquired conjunctivitis among neonatal intensive care unit patients. Pediatr. Infect. Dis. J. 24:586-589.[CrossRef][Medline]
16. Inoue, Y. 2002. Ocular infections in patients with atopic dermatitis. Int. Ophthalmol. Clin. 42:55-69.[Medline]
17. Kishimoto, H., C. D. Surh, and J. Sprent. 1998. A role for Fas in negative selection of thymocytes in vivo. J. Exp. Med. 187:1427-1438.[Abstract/Free Full Text]
18. Ly, C. N., J. N. Pham, P. R. Badenoch, S. M. Bell, G. Hawkins, D. L. Rafferty, and K. A. McClellan. 2006. Bacteria commonly isolated from keratitis specimens retain antibiotic susceptibility to fluoroquinolones and gentamicin plus cephalothin. Clin. Exp. Ophthalmol. 34:44-50.[CrossRef][Medline]
19. Madsen, J. M. 2001. Toxins as weapons of mass destruction: a comparison and contrast with biological-warfare and chemical-warfare agents. Clin. Lab. Med. 21:593-605.[Medline]
20. Mattix, M. E., R. E. Hunt, C. L. Wilhelmsen, A. J. Johnson, and W. B. Baze. 1995. Aerosolized staphylococcal enterotoxin B-induced pulmonary lesions in rhesus monkeys (Macaca mulatta). Toxicol. Pathol. 23:262-268.[Medline]
21. Nakata, K., Y. Inoue, J. Harada, N. Maeda, H. Watanabe, Y. Tano, Y. Shimomura, S. Harino, and M. Sawa. 2000. A high incidence of Staphylococcus aureus colonization in the external eyes of patients with atopic dermatitis. Ophthalmology 107:2167-2171.[CrossRef][Medline]
22. Oshima, Y., M. Ohji, Y. Inoue, J. Harada, M. Motokura, Y. Saito, K. Emi, and Y. Tano. 1999. Methicillin-resistant Staphylococcus aureus infections after scleral buckling procedures for retinal detachments associated with atopic dermatitis. Ophthalmology 106:142-147.[CrossRef][Medline]
23. Proft, T., and J. D. Fraser. 2003. Bacterial superantigens. Clin. Exp. Immunol. 133:299-306.[CrossRef][Medline]
24. Rajagopalan, G., K. Iijima, M. Singh, H. Kita, R. Patel, and C. S. David. 2006. Intranasal exposure to bacterial superantigens induces airway inflammation in HLA class II transgenic mice. Infect. Immun. 74:1284-1296.[Abstract/Free Full Text]
25. Rajagopalan, G., M. Sen, and C. S. David. 2004. In vitro and in vivo evaluation of staphylococcal superantigen peptide antagonists. Infect. Immun. 72:6733-6737.[Abstract/Free Full Text]
26. Rajagopalan, G., M. Sen, M. Singh, N. Murali, K. A. Nath, K. Iijima, H. Kita, A. A. Leontovich, G. Unnikrishnan, R. Patel, and C. S. David. 2006. Intranasal exposure to staphylococcal enterotoxin B elicits an acute systemic inflammatory response. Shock 25:647-656.
27. Rajagopalan, G., M. Singh, M. Sen, N. Murali, K. A. Nath, and C. S. David. 2005. Endogenous superantigens shape response to exogenous superantigens. Clin. Diagn. Lab. Immunol. 12:1119-1122.[Medline]
28. Rajagopalan, G., M. K. Smart, E. V. Marietta, and C. S. David. 2002. Staphylococcal enterotoxin B-induced activation and concomitant resistance to cell death in CD28-deficient HLA-DQ8 transgenic mice. Int. Immunol. 14:801-812.[Abstract/Free Full Text]
29. Roy, C. J., K. L. Warfield, B. C. Welcher, R. F. Gonzales, T. Larsen, J. Hanson, C. S. David, T. Krakauer, and S. Bavari. 2005. Human leukocyte antigen-DQ8 transgenic mice: a model to examine the toxicity of aerosolized staphylococcal enterotoxin B. Infect. Immun. 73:2452-2460.[Abstract/Free Full Text]
30. Rusnak, J. M., M. Kortepeter, R. Ulrich, M. Poli, and E. Boudreau. 2004. Laboratory exposures to staphylococcal enterotoxin B. Emerg. Infect. Dis. 10:1544-1549.[Medline]
31. Seal, D., L. Ficker, M. Ramakrishnan, and P. Wright. 1990. Role of staphylococcal toxin production in blepharitis. Ophthalmology 97:1684-1688.[Medline]
32. Shanmuganathan, V. A., M. Armstrong, A. Buller, and A. B. Tullo. 2005. External ocular infections due to methicillin-resistant Staphylococcus aureus (MRSA). Eye 19:284-291.[CrossRef][Medline]
33. Shoji, J., H. Kato, M. Kitazawa, N. Inada, and M. Sawa. 2003. Evaluation of staphylococcal enterotoxin-specific Ige antibody in tears in allergic keratoconjunctival disorders. Jpn. J. Ophthalmol. 47:609-611.[CrossRef][Medline]
34. Tabuchi, K., N. Inada, J. Shoji, M. Sawa, and H. Kato. 2004. The relationship between Staphylococcus aureus and atopic keratoconjunctivitis. Nippon Ganka Gakkai Zasshi 108:397-400. (In Japanese.)[Medline]
35. Thakur, A., A. Clegg, A. Chauhan, and M. D. Willcox. 1997. Modulation of cytokine production from an epiocular corneal cell culture model in response to Staphylococcus aureus superantigen. Aust. N. Z. J. Ophthalmol. 25(Suppl. 1):S43-S45.[Medline]
36. Tuft, S. J., M. Ramakrishnan, D. V. Seal, D. M. Kemeny, and R. J. Buckley. 1992. Role of Staphylococcus aureus in chronic allergic conjunctivitis. Ophthalmology 99:180-184.[Medline]
37. Yeung, R. S., J. M. Penninger, T. Kundig, W. Khoo, P. S. Ohashi, G. Kroemer, and T. W. Mak. 1996. Human CD4 and human major histocompatibility complex class II (DQ6) transgenic mice: supersensitivity to superantigen-induced septic shock. Eur. J. Immunol. 26:1074-1082.[Medline]
38. Zhu, H., and M. D. P. Willcox. 1999. Detection of staphylococcal superantigens from contact-lens-induced inflammatory diseases. Aust. N. Zealand J. Ophthalmol. 27:237-240.[CrossRef]

Infection and Immunity, October 2006, p. 6016-6019, Vol. 74, No. 10
0019-9567/06/$08.00+0     doi:10.1128/IAI.00671-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rajagopalan, G.
Right arrow Articles by David, C. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rajagopalan, G.
Right arrow Articles by David, C. S.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
J. Bacteriol. J. Virol. Eukaryot. Cell
Microbiol. Mol. Biol. Rev. Clin. Vaccine Immunol. All ASM Journals